Integrative omics reveals candidate drug-repurposing targets in Tritrichomonas foetus.

Opis bibliograficzny

Integrative omics reveals candidate drug-repurposing targets in Tritrichomonas foetus. [AUT.] JOANNA DĄBROWSKA, MACIEJ KOCHANOWSKI, JACEK SROKA. BMC Genomics. DOI: 10.1186/s12864-026-13330-5
Skopiowane!
Kliknij opis aby skopiować do schowka

Szczegóły publikacji

Źródło:
Rok:2026
Język:angielski
Charakter formalny:Artykuł w czasopismie
Typ MNiSW/MEiN:Praca Oryginalna

Streszczenia

Feline tritrichomonosis is a globally distributed chronic large-bowel diarrhoea of cats caused by the flagellated protozoan Tritrichomonas foetus. The only drug with demonstrated clinical efficacy is the off-label 5-nitroimidazole ronidazole, which has a narrow therapeutic window and against which clinical resistance has now been documented across three continents. The last comprehensive in silico drug-target prioritisation for T. foetus was published a decade ago and proposed 113 candidates based on homology to ChEMBL alone; the genomic and pharmacological landscape has since changed substantially, but no integrative reanalysis has been undertaken. Results Starting from the predicted proteome of strain K (25030 proteins), an integrative subtractive pipeline combining filtering against the feline host proteome, three pharmacological reference databases, essential-gene resources from three model eukaryotes, and the PHI-base virulence reference returned 433 priority candidates. Application of the same pipeline to the chromosome-scale strain KV-1 assembly yielded 436 candidates, with 66% cross-strain recovery as reciprocal best hits. Gene-level expression analysis showed that 82.7% of priority candidates were actively transcribed in the feline isolate G10/1, and a proof-of-concept docking screen against three top-ranked candidates recovered internally consistent, structure-based affinity rankings that await experimental validation. Nine of the ten most highly expressed candidates correspond to a protein family with clinically advanced small-molecule inhibitors; the tenth, a Rab4B GTPase, belongs to the broader, pharmacologically tractable Ras/GTPase superfamily but has no Rab4B-specific inhibitor characterised to date.

Identyfikatory

e-ISSN: 1471-2164
BPP ID: (7, 10060) wydawnictwo ciągłe #10060

Metryki

140,00
Punkty MNiSW/MEiN
3,900
Impact Factor
Q2
WoS
0
Index Copernicus
0
Punktacja wewnętrzna

Eksport cytowania

Wsparcie dla menedżerów bibliografii:
Ta strona wspiera automatyczny import do Zotero, Mendeley i EndNote. Użytkownicy z zainstalowanym rozszerzeniem przeglądarki mogą zapisać tę publikację jednym kliknięciem - ikona pojawi się automatycznie w pasku narzędzi przeglądarki.

Skopiowane!

Informacje dodatkowe

Status:po korekcie
Praca recenzowana:tak
Rekord utworzony:22 października 2026 09:56
Ostatnia aktualizacja:5 listopada 2026 11:15